Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF
Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF Summary
For the complete range of Coronavirus-related proteins
Met1-Thr411, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
MERS-CoV, which causes the Middles East Respiratory Syndrome (MERS), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). While the S, E and M proteins build up the viral envelope, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (1, 2). The MERS-CoV N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an Intrinsically Disordered Region (3) and an RNA binding domain (4), the linker region interacts with the M protein and the C-terminal region contains a self-association domain (1, 2). The MERS-CoV N protein shares 46.3% and 4.5% amino acid sequence identity with SARS-CoV-1 and SARS-CoV-2 N protein, respectively. MERS-CoV N proteins have been shown to inhibit Type I Interferon(IFN) production(1). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity, making it a promising therapeutic target (5-7).
- Li, Y. et al. (2019) Engineering. 5:940.
- Hurst, K. R. et al. (2009) J. Virol. 83:7221.
- Wang, Y. et al. (2015) Acta. Crystallogr. F. Struct. Biol. Commun. 71:977.
- Papageorgiou, N. et al. (2016) Acta. Crystallogr. D. Struct. Biol. 72:192.
- Che, X. Y. et al. (2004) J. Clin. Microbiol. 42:2629.
- Guan, M. et al. (2004) Clin. Diagn. Lab. Immunol. 11:287.
- Chang, C-K. et al.(2016) Drug Discov. Today. 21:562.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF and earn rewards!
Have you used Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image